Funded, March 30, 2015
Ipilimumab for the first–line treatment of advanced (unresectable or metastatic) melanoma dosed at 3 mg/kg every 3 weeks for 4 doses. Only patients with a documented response maintained for 6 months are eligible for re–treatment. 

Funded, July 1, 2015 

Unresectable stage IIIC or stage IV melanoma:
– ECOG 0 or 1
– Adequate hepatic and renal function
– Life expectancy of at least four months
– Access to a treatment centre with expertise to manage immune-mediated adverse reactions of ipilimumab
– A BCCA “Compassionate Access Program” request with appropriate clinical information for each patient must be approved prior to treatment 

Funded, July 21, 2016
For the treatment of Unresectable or Metastatic Melanoma when used in combination with Tafinlar (dabrafenib). 

Funded, July 15, 2015 

Initial treatment: As a single agent for the first– line treatment of primary cutaneous unresectable stage IIIC or IV melanoma in patients (regardless of BRAF mutation status) or who have received at least one prior systemic treatment (excluding ipilimumab) for advanced melanoma, have an ECOG performance status (PS) ≤ 1 and are not currently receiving immunosuppressive therapy. If brain metastases are present, patients should be asymptomatic or stable. Re–induction: At the time of disease progression, the patient has had stable disease for at least three months or has previously experienced a complete or partial response. 

For the treatment of unresectable or metastatic melanoma in patients who have failed or do not tolerate other systemic therapy for advanced disease. 

Funded, April 1, 2015 

As a single agent for the treatment of primary cutaneous unresectable stage IIIC or IV melanoma in patients (regardless of BRAF mutation status) as first– line therapy or who have received at least one prior systemic treatment (excluding ipilimumab) for advanced melanoma , have an ECOG performance status (PS) ≤ 1 and are not currently receiving immunosuppressive therapy. If brain
metastases are present, patients should be asymptomatic or stable. 

Funded, April 1, 2015
For the first–line treatment of patients who are at least 18 years old with advanced melanoma (i.e. primary cutaneous unresectable state IIIC or IV melanoma or metastatic melanoma), regardless of BRAF mutation status, who have an ECOG PS score ≤1 and are not currently receiving immunosuppressive therapy. If a patient has brain metastasis, then he or she must be asymptomatic or stable. Dosage Regimen: 3 mg/kg every three weeks for four doses. Exclusion Criteria: Requests for dose escalation up to 10  mg/kg will not be considered. 

 – Maintenance or reinduction requests in the first-line setting will not be considered.  

 – Patients who have used ipilimumab for advanced/ metastatic melanoma in the first-line setting are not eligible for funding in the second-line setting. 

Funded
First– line treatment of adult patients with stage IIIC or IV melanoma, regardless of BRAF mutation status, who have an ECOG performance status of 0 or 1, and are not currently receiving immunosuppressive therapy.
– If brain metastases are present, patients should be asymptomatic or stable.
– Ipilimumab induction is funded for four (4) doses at 3 mg/kg administered every 3 weeks.
– Induction therapy is discontinued if four doses cannot be administered within 16 weeks. 

Note:  Re–induction with a further 4 doses may be considered in patients who remain ECOG 0 or 1 and who experienced clinical benefit (e.g., partial/complete response or stable disease) for a
minimum of 3 months following first induction or who achieved a partial or complete response to first induction. 

Funded, July 10, 2019
Listed for all lines of therapy in Quebec for patients with no or treated and stable brain metastases and  ECOG performance status of 0-1. 

Funded, May 1, 2015 

First–line treatment of adult patients with stage IIIC or IV melanoma, regardless of BRAF mutation status, who have an ECOG performance status of 0 or 1, and are not currently receiving immunosuppressive therapy.